Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
Go back to Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 29.03 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.03 | 52 Week High | $117.12 | |||
| Open | $29.03 | 52 Week Low | $46.52 | |||
| Day High | $29.03 | P/E | N/A | |||
| Day Low | $29.03 | EPS | $-1.97 | |||
| Volume | 460 | |||||
